Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Warning Eclipses Sun, SPARC But Investors Stand Pat

This article was originally published in Scrip

Executive Summary

Shares of Sun Pharmaceutical Industries Ltd and Sun Pharma Advanced Research Company Ltd (SPARC) were pounded in early trade Dec. 21 on Indian bourses after the weekend announcement of an FDA warning letter for Sun's Halol site, though analysts appeared cautiously optimistic about the firm's bounce-back prospects despite the short-term pain.

You may also be interested in...



Baclofen Setback Forces Sun R&D Arm Towards Difficult Choices

Sun Pharma Advanced Research Company’s baclofen GRS has failed to meet its primary endpoint in a US Phase III study, posing several tough questions for the firm. It may have to advance partnering plans for some assets and also review its cash flow situation closely.

Keeping Track: New Submissions In Bladder Cancer, HCV And Diabetes; Avastin Label Expands

The latest drug development news and highlights from our FDA Performance Tracker.

SPARC Pins Hope On Halol Plant For Elepsia FDA Nod But Has Plan B

Sun Pharma’s research arm SPARC says it’s still convinced its Indian parent’s troubled Halol plant offers the shortest route to US regulatory approval for its epilepsy drug Elepsia and its glaucoma medicine Xelpros. US FDA clearances of both drugs have been stalled by manufacturing lapses at Sun Pharma’s factory. But SPARC says it has a manufacturing 'plan B' if necessary.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC064040

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel